Cutaneous squamous cell carcinoma is the second most common form of skin cancer, with an estimated 1 million cases treated in the United States each year. Although most cSCCs are localized and can be easily treated, approximately 5% of patients will experience local recurrence, 4% will develop nodal metastases, and up to 2% will die of the disease. In addition to the small but significant number of deaths attributed to cSCC each year, the disease and its associated precancerous skin lesions contribute to a large financial burden of more than $4.5 billion annually in the United States.
